desloratadine | Elisha tablets 5 mg 30 pcs.
Special Price
$19.40
Regular Price
$28.00
In stock
SKU
BID476830
Release form
Tablets.
Tablets.
Release form
Tablets.
Packing
30 pcs.
Pharmacological action
Pharmaceutical group: Antiallergic agent - H1-histamine receptor blocker.
Pharmaceutical action: Desloratadine is a long-acting antihistamine. It is the primary active metabolite of loratadine.
Inhibits a cascade of allergic inflammation reactions, including release of pro-inflammatory cytokines, including IL-4, IL-6, IL-8, IL-13, release of pro-inflammatory chemokines (RANTES), production of superoxide anions by activated polymorphonuclear neutrophils, adhesion and chemotaxis of eosinophils, isolation of adhesion molecules such as P-like IgE-mediated release of histamine, PG D2 and LT C4.
Thus, it prevents the development and facilitates the course of allergic reactions, has an antipruritic and antiexudative effect, reduces capillary permeability, prevents the development of tissue edema, smooth muscle spasm.
The drug does not affect the central nervous system, practically does not have a sedative effect (does not cause drowsiness) and does not affect the speed of psychomotor reactions. Does not cause prolongation of the QT interval on the ECG.
The drug begins within 30 minutes after ingestion and lasts for 24 hours.
Pharmacokinetics: The concentration of desloratadine in plasma can be determined 30 minutes after administration. Desloratadine is well absorbed, Tmax on average 3 hours. Does not penetrate the BBB. The bioavailability of desloratadine was proportional to the dose in the range of 5 to 20 mg. Communication with plasma proteins is 83–87%.
When applying a dose of desloratadine (5 to 20 mg) once a day for 14 days, there are no signs of clinically significant cumulation of the drug.
Concomitant use of food or grapefruit juice does not affect the distribution of desloratadine when used at a dose of 7.5 mg once a day.
Desloratadine is not an inhibitor of CYP3A4 and CYP2D4 and is not a substrate or inhibitor of P-glycoprotein. Intensively metabolized in the liver by hydroxylation with the formation of 3-OH-desloratadine, combined with glucuronide. Only a small portion of the oral dose is excreted by the kidneys.
Indications
Allergic rhinitis (sneezing, nasal discharge, itching and nasal congestion, itching and redness of the eyes, lacrimation, itching in the palate)
urticaria (itching, rash).
Contraindications
Hypersensitivity
lactase deficiency, lactose intolerance, glucose-galactose malabsorption
age up to 12 years (efficacy and safety have not been established).
Precautions: severe renal failure.
Use during pregnancy and lactation
Contraindicated in pregnancy and lactation.
Special instructions
In patients with a high degree of renal failure, the drug Eliseus should be administered under medical supervision.
The drug is contraindicated in patients with rare hereditary manifestations of galactose intolerance, lactase deficiency or malabsorption syndrome of glucose and galactose.
Children. Efficacy and safety of the use of Elysia tablets in children under 12 years of age have not been established.
Influence on the ability to drive vehicles and work with mechanisms. Patients should be informed that in very rare cases, some people feel drowsiness, dizziness, which may affect their ability to drive a car and difficult equipment.
Dosage and Administration
Inside.
The drug Elisei is recommended to be taken at the same time of day. The tablet should be swallowed whole, without chewing, washed down with a small amount of water.
Adults and children from 12 years of age, the drug is prescribed in a dose of 5 mg (1 tab.) 1 time per day, regardless of food intake.
The duration of treatment depends on the severity and course of the disease.
Treatment of intermittent allergic rhinitis (the presence of symptoms less than 4 days a week or less than 4 weeks) must be carried out taking into account the anamnestic and clinical data: stop after the symptoms disappear and resume after their repeated occurrence.
In persistent allergic rhinitis (the presence of symptoms more than 4 days a week or more than 4 weeks), it is necessary to continue treatment throughout the entire period of contact with the allergen.
Side effects
Usually desloratadine is well tolerated, but sometimes side effects are possible. The most common side effects are fatigue, dryness of the oral mucosa and headache.
Mental disorders: hallucinations.
From the nervous system: headache, dizziness, drowsiness, insomnia, psychomotor hyperactivity, convulsions.
From the side of the heart: tachycardia, palpitations.
From the gastrointestinal tract: dry oral mucosa, diarrhea, abdominal pain, nausea, vomiting, dyspepsia.
From the hepatobiliary system: increased liver enzyme activity, increased bilirubin concentration, hepatitis.
From the side of the musculoskeletal system and connective tissue: myalgia.
General disorders: hypersensitivity reactions (including anaphylaxis, angioedema, dyspnea, itching, rashes and urticaria), increased fatigue.
overdose
Symptoms: No serious adverse reactions were observed in clinical trials using doses exceeding the recommended 5-fold. Sleepiness is possible.
Treatment: gastric lavage, administration of activated charcoal if necessary - symptomatic therapy. Desloratadine is not excreted by hemodialysis, the efficacy of its removal by peritoneal dialysis has not been established.
Deystvuyuschee substances
Desloratadine
Medicinal form
tablet
Appointment
Children over 12 years, Adults
Indications
Pollinosis, Allergy, Conjunctivitis, Runny nose, Diathesis, Allergic conjunctivitis, Urticaria, Dermatitis, Alle cal rhinitis
Possible product names
Elysees tablets 5 mg 30 pcs.
Farmak, Ukraine
Tablets.
Packing
30 pcs.
Pharmacological action
Pharmaceutical group: Antiallergic agent - H1-histamine receptor blocker.
Pharmaceutical action: Desloratadine is a long-acting antihistamine. It is the primary active metabolite of loratadine.
Inhibits a cascade of allergic inflammation reactions, including release of pro-inflammatory cytokines, including IL-4, IL-6, IL-8, IL-13, release of pro-inflammatory chemokines (RANTES), production of superoxide anions by activated polymorphonuclear neutrophils, adhesion and chemotaxis of eosinophils, isolation of adhesion molecules such as P-like IgE-mediated release of histamine, PG D2 and LT C4.
Thus, it prevents the development and facilitates the course of allergic reactions, has an antipruritic and antiexudative effect, reduces capillary permeability, prevents the development of tissue edema, smooth muscle spasm.
The drug does not affect the central nervous system, practically does not have a sedative effect (does not cause drowsiness) and does not affect the speed of psychomotor reactions. Does not cause prolongation of the QT interval on the ECG.
The drug begins within 30 minutes after ingestion and lasts for 24 hours.
Pharmacokinetics: The concentration of desloratadine in plasma can be determined 30 minutes after administration. Desloratadine is well absorbed, Tmax on average 3 hours. Does not penetrate the BBB. The bioavailability of desloratadine was proportional to the dose in the range of 5 to 20 mg. Communication with plasma proteins is 83–87%.
When applying a dose of desloratadine (5 to 20 mg) once a day for 14 days, there are no signs of clinically significant cumulation of the drug.
Concomitant use of food or grapefruit juice does not affect the distribution of desloratadine when used at a dose of 7.5 mg once a day.
Desloratadine is not an inhibitor of CYP3A4 and CYP2D4 and is not a substrate or inhibitor of P-glycoprotein. Intensively metabolized in the liver by hydroxylation with the formation of 3-OH-desloratadine, combined with glucuronide. Only a small portion of the oral dose is excreted by the kidneys.
Indications
Allergic rhinitis (sneezing, nasal discharge, itching and nasal congestion, itching and redness of the eyes, lacrimation, itching in the palate)
urticaria (itching, rash).
Contraindications
Hypersensitivity
lactase deficiency, lactose intolerance, glucose-galactose malabsorption
age up to 12 years (efficacy and safety have not been established).
Precautions: severe renal failure.
Use during pregnancy and lactation
Contraindicated in pregnancy and lactation.
Special instructions
In patients with a high degree of renal failure, the drug Eliseus should be administered under medical supervision.
The drug is contraindicated in patients with rare hereditary manifestations of galactose intolerance, lactase deficiency or malabsorption syndrome of glucose and galactose.
Children. Efficacy and safety of the use of Elysia tablets in children under 12 years of age have not been established.
Influence on the ability to drive vehicles and work with mechanisms. Patients should be informed that in very rare cases, some people feel drowsiness, dizziness, which may affect their ability to drive a car and difficult equipment.
Dosage and Administration
Inside.
The drug Elisei is recommended to be taken at the same time of day. The tablet should be swallowed whole, without chewing, washed down with a small amount of water.
Adults and children from 12 years of age, the drug is prescribed in a dose of 5 mg (1 tab.) 1 time per day, regardless of food intake.
The duration of treatment depends on the severity and course of the disease.
Treatment of intermittent allergic rhinitis (the presence of symptoms less than 4 days a week or less than 4 weeks) must be carried out taking into account the anamnestic and clinical data: stop after the symptoms disappear and resume after their repeated occurrence.
In persistent allergic rhinitis (the presence of symptoms more than 4 days a week or more than 4 weeks), it is necessary to continue treatment throughout the entire period of contact with the allergen.
Side effects
Usually desloratadine is well tolerated, but sometimes side effects are possible. The most common side effects are fatigue, dryness of the oral mucosa and headache.
Mental disorders: hallucinations.
From the nervous system: headache, dizziness, drowsiness, insomnia, psychomotor hyperactivity, convulsions.
From the side of the heart: tachycardia, palpitations.
From the gastrointestinal tract: dry oral mucosa, diarrhea, abdominal pain, nausea, vomiting, dyspepsia.
From the hepatobiliary system: increased liver enzyme activity, increased bilirubin concentration, hepatitis.
From the side of the musculoskeletal system and connective tissue: myalgia.
General disorders: hypersensitivity reactions (including anaphylaxis, angioedema, dyspnea, itching, rashes and urticaria), increased fatigue.
overdose
Symptoms: No serious adverse reactions were observed in clinical trials using doses exceeding the recommended 5-fold. Sleepiness is possible.
Treatment: gastric lavage, administration of activated charcoal if necessary - symptomatic therapy. Desloratadine is not excreted by hemodialysis, the efficacy of its removal by peritoneal dialysis has not been established.
Deystvuyuschee substances
Desloratadine
Medicinal form
tablet
Appointment
Children over 12 years, Adults
Indications
Pollinosis, Allergy, Conjunctivitis, Runny nose, Diathesis, Allergic conjunctivitis, Urticaria, Dermatitis, Alle cal rhinitis
Possible product names
Elysees tablets 5 mg 30 pcs.
Farmak, Ukraine
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review